5IU.F ISOFOL MEDICAL AB
- Market cap
- EUR 35.3M
- P/E
- -
- P/B
- 4.39x
- ROE
- -64.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5IU.F undervalued?
Graham numberThe Graham number of ISOFOL MEDICAL AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ISOFOL MEDICAL AB fundamental analysis
No fundamental analysis for ISOFOL MEDICAL AB yet.
ISOFOL MEDICAL AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ISOFOL MEDICAL AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
Full company profileISOFOL MEDICAL AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ISOFOL MEDICAL AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 22.4M | 12.8M | 721K | 0.00 | 0.00 | 0.00 |
| Operating Income | -204M | -168M | -41.7M | -47.2M | -56.0M | -63.9M |
| EBITDA | - | -160M | -37.0M | -43.5M | -54.2M | -61.6M |
| Net Income | -200M | -160M | -37.1M | -43.5M | -54.2M | -61.6M |
| EPS | -1.09 | -0.87 | -0.20 | -0.24 | -0.19 | -0.19 |
| Balance Sheet | ||||||
| Total Assets | 401M | 210M | 141M | 98.4M | 129M | 119M |
| Total Liabilities | 83.1M | 51.4M | 19.2M | 20.5M | 21.5M | 23.5M |
| Shareholders' Equity | 318M | 159M | 121M | 77.9M | 108M | 95.0M |
| Cash & Short-term Investments | 379M | 191M | 138M | 96.2M | 42.0M | 29.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -188M | -193M | -52.5M | -42.0M | -51.9M | -61.0M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -188M | -193M | -52.5M | -42.0M | -51.9M | -61.0M |
| Ratios | ||||||
| ROE | -62.9% | -100.8% | -30.5% | -55.8% | -50.2% | -64.8% |
| ROA | -49.9% | -76.1% | -26.4% | -44.2% | -41.9% | -51.9% |
| Net Profit Margin | -893.7% | -1,248.7% | -5,141.6% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ISOFOL MEDICAL AB dividends
ISOFOL MEDICAL AB has not paid dividends in the last 5 fiscal years.
Who owns ISOFOL MEDICAL AB
- Insiders 26.07%
- Institutions 15.00%
- Public & others 58.93%
- Shares outstanding 320M
- Free float 228M
ISOFOL MEDICAL AB company profile
- Company name
- ISOFOL MEDICAL AB
- Ticker
- 5IU.F
- ISIN
- SE0009581051
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- Biotech Center, Gothenburg, Sweden, 413 46
- Phone
- 46 0 31 13 73 31
- Website
- isofolmedical.com
About ISOFOL MEDICAL AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
ISOFOL MEDICAL AB management
4- Mr. Petter Segelman Lindqvist M.Sc.Chief Executive Officer · born 1981
- Ms. Margareta Hagman M.Sc.Chief Financial Officer · born 1966
- Dr. Roger Tell M.D., Ph.D.Chief Medical Officer · born 1965
- Mr. John ProffettBusiness Development & Chief Business Officer